The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
EUFOREA consensus on biologics for CRSwNP with or without asthma
Open accessAbstract
Novel therapies such as type 2 targeting biologics are emerging treatment options for patients with chronic inflammatory respiratory diseases, fulfilling the needs of severely uncontrolled patients. The majority of patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and over half of patients with asthma show a type 2 inflammatory signature in sinonasal mucosa and/or lungs. Importantly, both chronic respiratory diseases are frequent comorbidities, ensuring alleviation of both upper and lower airway pathology by systemic biological therapy. Type 2‐targeting biologics such as anti‐IgE, anti‐IL4Rα, anti‐IL5, and anti‐IL5Rα have entered the market for selected pheno/endotypes of asthma patients and may soon also become available for CRSwNP patients. Given the high prevalence of chronic respiratory diseases and the high cost associated with biologics, patient selection is crucial in order to implement such therapies into chronic respiratory disease care pathways. The European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) organized a multidisciplinary Expert Board Meeting to discuss the positioning of biologics into the care pathways for CRSwNP patients with and without comorbid asthma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
European Position Paper on Rhinosinusitis and Nasal Polyps 2020
Fokkens, W. J., Lund, V. J., Hopkins, C., Hellings, P. W., Kern, R., Reitsma, S., Toppila-Salmi, S., Bernal-Sprekelsen, M., Mullol, J., Alobid, I., et al. (2020) · Rhinology journal · doi:10.4193/rhin20.600 · Cited by 5,882
Self-citationInternational ERS/ATS guidelines on definition, evaluation and treatment of severe asthma
Chung, K. F., Wenzel, S. E., Brozek, J. L., Bush, A., Castro, M., Sterk, P. J., Adcock, I. M., Bateman, E. D., Bel, E. H., Bleecker, E. R., et al. (2014) · European Respiratory Journal · doi:10.1183/09031936.00202013 · Cited by 3,926
Global strategy for asthma management and prevention: GINA executive summary
Bateman, E. D., Hurd, S. S., Barnes, P. J., Bousquet, J., Drazen, J. M., FitzGerald, M., Gibson, P., Ohta, K., O'Byrne, P., Pedersen, S. E., et al. (2008) · European Respiratory Journal · doi:10.1183/09031936.00138707 · Cited by 3,203
Self-citationTwo Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610020 · Cited by 2,110
Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma
Castro, M., Corren, J., Pavord, I. D., Maspero, J., Wenzel, S., Rabe, K. F., Busse, W. W., Ford, L., Sher, L., FitzGerald, J. M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1804092 · Cited by 1,986
Blauvelt, A., de Bruin-Weller, M., Gooderham, M., Cather, J. C., Weisman, J., Pariser, D., Simpson, E. L., Papp, K. A., Hong, H. C.-H., Rubel, D., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31191-1 · Cited by 1,261
Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma
Rabe, K. F., Nair, P., Brusselle, G., Maspero, J. F., Castro, M., Sher, L., Zhu, H., Hamilton, J. D., Swanson, B. N., Khan, A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1804093 · Cited by 1,184
Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers
Tomassen, P., Vandeplas, G., Van Zele, T., Cardell, L.-O., Arebro, J., Olze, H., Förster-Ruhrmann, U., Kowalski, M. L., Olszewska-Ziąber, A., Holtappels, G., et al. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.12.1324 · Cited by 1,162
Self-citationChronic rhinosinusitis in Europe - an underestimated disease. A GA2LEN study
Hastan, D., Fokkens, W. J., Bachert, C., Newson, R. B., Bislimovska, J., Bockelbrink, A., Bousquet, P. J., Brozek, G., Bruno, A., Dahlén, S. E., et al. (2011) · Allergy · doi:10.1111/j.1398-9995.2011.02646.x · Cited by 1,112
Self-citationOlfactory Disorders and Quality of Life--An Updated Review
Croy, I., Nordin, S., & Hummel, T. (2014) · Chemical Senses · doi:10.1093/chemse/bjt072 · Cited by 917
Cited by
EPOS2020: A Major Step Forward
Fokkens, W. J. (2020) · Rhinology journal · doi:10.4193/rhin20.401 · Cited by 1,240
Self-citationExecutive Summary of EPOS 2020 Including Integrated Care Pathways
Fokkens, W. J., Lund, V. J., Hopkins, C., Hellings, P. W., Kern, R., Reitsma, S., Toppila-Salmi, S., Bernal-Sprekelsen, M., & Mullol, J. (2020) · Rhinology journal · doi:10.4193/rhin20.601 · Cited by 533
Self-citationPathogenesis of allergic diseases and implications for therapeutic interventions
Wang, J., Zhou, Y., Zhang, H., Hu, L., Liu, J., Wang, L., Wang, T., Zhang, H., Cong, L., & Wang, Q. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01344-4 · Cited by 376
Type 2 immunity in allergic diseases
Ogulur, I., Mitamura, Y., Yazici, D., Pat, Y., Ardicli, S., Li, M., D’Avino, P., Beha, C., Babayev, H., Zhao, B., et al. (2025) · Cellular & Molecular Immunology · doi:10.1038/s41423-025-01261-2 · Cited by 362
Bachert, C., Han, J. K., Wagenmann, M., Hosemann, W., Lee, S. E., Backer, V., Mullol, J., Gevaert, P., Klimek, L., Prokopakis, E., et al. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.11.013 · Cited by 355
Self-citationType 2 inflammation in asthma and other airway diseases
Maspero, J., Adir, Y., Al-Ahmad, M., Celis-Preciado, C. A., Colodenco, F. D., Giavina-Bianchi, P., Lababidi, H., Ledanois, O., Mahoub, B., Perng, D.-W., et al. (2022) · ERJ Open Research · doi:10.1183/23120541.00576-2021 · Cited by 315
Burden of Disease in Chronic Rhinosinusitis with Nasal Polyps
Bachert, C., Bhattacharyya, N., Desrosiers, M., & Khan, A. H. (2021) · Journal of Asthma and Allergy · doi:10.2147/jaa.s290424 · Cited by 294
Self-citationRole of IL‐25, IL‐33, and TSLP in triggering united airway diseases toward type 2 inflammation
Hong, H., Liao, S., Chen, F., Yang, Q., & Wang, D. (2020) · Allergy · doi:10.1111/all.14526 · Cited by 272
Metadata
- Authors
- Fokkens, W. J., Lund, V., Bachert, C., Mullol, J., Bjermer, L., Bousquet, J., Canonica, G. W., Deneyer, L., Desrosiers, M., Diamant, Z., Han, J., Heffler, E., Hopkins, C., Jankowski, R., Joos, G., Knill, A., Lee, J., Lee, S. E., Mariën, G., Pugin, B., Senior, B., Seys, S. F., & Hellings, P. W.
- Venue
- Allergy
- Publisher
- Wiley
- Published
- 2019-07-15
- Volume
- 74
- Issue
- 12
- Pages
- 2312-2319
- ISSN
- 0105-4538 (ISSN-L)
- 1398-9995
- OpenAlex
- W2946585587
- Cited by
- 390
- References
- 69
- FWCI
- 30.69
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.